Please assess the completion status of the following clinical trial:

Trial Title: The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the Institute of Medicine (IOM) criteria for ME/CFS~* Completing the clinically indicated invasive cardiopulmonary exercise test (iCPET)~Exclusion Criteria:~* Obesity (BMI \> 30 kg/m2)~* Non-controlled asthma~* Anemia (Hb \< 10 g/dl)~* Active or treated cancer~* History of interstitial lung disease (ILD)~* Chronic obstructive pulmonary disease (COPD)~* Pulmonary hypertension (PH)~* Congestive heart failure (CHF)~* Active arrhythmias~* Valvular heart disease~* Coronary artery disease (CAD)~* Other conditions that could predict a limitation or not completion of the study.~* Pregnancy~* Submaximal testing in clinically indicated iCPET~* Pulmonary mechanical limitation to exercise in clinically indicated iCPET.~* Pulmonary arterial hypertension in clinically indicated iCPET.~* Pulmonary venous hypertension in clinically indicated iCPET.~* Exercise induced pulmonary arterial hypertension in clinically indicated iCPET.~* Exercise induced pulmonary venous hypertension in clinically indicated iCPET.~* Persistent hypotension during or after the clinically indicated iCPET.~* Refractory arrhythmia during or after the clinically indicated level 3 CPET.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug - Pyridostigmine (Type: ACTIVE_COMPARATOR): Pyridostigmine 60 mg by mouth as a one time dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth as a one time dose

Based on this trial design, predict the completion outcome and termination type (if applicable).